Advances in Acute-On-Chronic Liver Failure

Advances in Acute-On-Chronic Liver Failure (ACLF)

Lecture Summary — Rajiv Jalan, MD

1. Main Clinical Topics Discussed

• Pathophysiology, classification, and prognosis of Acute-on-Chronic Liver Failure (ACLF)
• Reclassification of cirrhosis as a clinical continuum rather than a staged disease
• The CLIF Organ Failure scoring system and its derivatives
• Role of systemic inflammation and Cirrhosis-Associated Immune Dysfunction (CAID) in ACLF
• Clinical utility of prognostic scores for treatment decisions, including futility assessment
• Emerging therapeutic targets and the evolving role of liver transplantation in ACLF

2. Key Learning Points, Guidelines, and Recommendations

• ACLF should be understood as a dynamic, multi-organ syndrome, not a single-organ (liver) failure; mortality risk is driven by failure of any combination of six organ systems: liver, kidney, brain, coagulation, circulation, and respiration
• Cirrhosis exists on a continuum from compensated (stable, at home) → acute decompensation → pre-ACLF → ACLF grades 1–3, with prognosis worsening progressively along this trajectory
• Acute decompensating events requiring hospitalization are defined by five liver-related triggers: infection, variceal bleeding, ascites, hepatic encephalopathy, and jaundice (validated in the PREDICT study)
• Reversibility is possible: a proportion of ACLF patients can recover spontaneously, emphasizing the importance of early intervention
• Futility guidance: In patients not candidates for liver transplantation, a CLIF-C ACLF score >70 at days 3–5 of ICU admission is associated with near-universal mortality and can inform discussions about withdrawal of intensive care support
• Systemic inflammation (captured by markers such as WBC, CRP, TNF, IL-10) is a critical and previously underrecognized pathophysiologic driver, distinct from the classical peripheral arterial vasodilation hypothesis (Schrier hypothesis, 1988)

3. Specific Clinical Data, Statistics, and Study Results Cited

• Global burden: Cirrhosis causes approximately 2 million deaths annually worldwide; this figure has remained unchanged over 30–40 years
• US economic burden: Liver disease costs an estimated $18 billion annually in the United States
• COVID-19 comparison: ~20 million deaths attributed to the pandemic over several years, underscoring the comparable but underappreciated mortality burden of cirrhosis
• ACLF prevalence at hospitalization: Approximately 30% of patients presenting with acute decompensation already have ACLF; an additional ~10% develop ACLF during hospitalization
• 28-day mortality by ACLF grade (CLIF Organ Failure Score, validated in the CANONIC study and internationally):

- ACLF Grade 1 (single kidney failure or other single organ failure with mild renal/brain dysfunction): ~20% mortality

- ACLF Grade 2 (2 organ failures): ~32% mortality

- ACLF Grade 3 (3–6 organ failures): 68–90% mortality

- No ACLF: very low short-term mortality

• Spontaneous recovery rates:

- ACLF Grade 1: ~55% resolve; mortality approaches that of non-ACLF patients upon resolution

- ACLF Grade 2–3: progressively lower rates of spontaneous recovery

• International validation: CLIF classification validated in Europe (CANONIC study), China, Korea, the United States, and Latin America
• Non-ACLF acute decompensation subtypes (from the PREDICT study): stable decompensated cirrhosis (very low mortality risk), unstable decompensated cirrhosis (intermediate risk), and pre-ACLF (high short-term mortality risk, comparable to ACLF Grade 1–2)

4. Practical Takeaways for Clinicians

• Adopt a continuum-based framework: Recognize that any acutely decompensated